Learn the key differences between CIDP and GBS, including causes, onset, and treatments, to ensure you get the correct diagnosis.

Please provide your email address to receive an email when new articles are posted on . Hyqvia is an immune globulin infusion (human) 10% solution. It was previously approved by the EC for primary ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Vyvgart Hytrulo in a once-weekly, 30- to 90-second subcutaneous injection to treat adults ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) results in disability through immune-mediated nerve injury, which can lead to irreversible deficits after the inflammatory component of CIDP is ...

The SC formulation of efgartigimod alfa plus hyaluronidase-qvfc is currently marketed under the trade name Vyvgart Hytrulo and is approved for the treatment of generalized myasthenia gravis. The Food ...

Results showed 94.4% of study participants demonstrated an improvement in functional disability. The Food and Drug Administration (FDA) has approved Gammagard Liquid ® (immune globulin infusion 10% ...

(RTTNews) - Takeda (TAK) said that the European Commission approved Hyqvia as maintenance therapy in patients of all ages with chronic inflammatory demyelinating polyneuropathy or CIDP after ...

(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy. VYVDURA is ...

Explore comprehensive treatments for CIDP, including corticosteroids, plasma exchange, immunoglobulin therapy, and others.

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administration ...